Introduction
The cellular prion protein is responsible for transmissible spongiform encephalopathies (TSE) that can affect several mammals including humans (1) . The common central event in prion pathologies is the conversion of the host-encoded cellular prion protein (PrP c ) into a pathogenic, insoluble and partially protease-resistant isoform (PrP sc ) that aggregates and accumulates in specific brain areas, triggers neuronal degeneration and ultimately leads to dementia and death (2) .
Besides its implication in the development of TSE, it was postulated that PrP c could fulfill physiological functions. Indeed, it has been suggested that PrP c could participate in lymphocyte activation, cellular adhesion processes, neuronal growth, synaptogenesis, cellular signaling and cell survival/apoptosis (for review see (3) ).
The cellular prion protein is physiologically cleaved at the 111/112 peptidyl bond, thereby generating the so-called N1 amino-terminal fragment and its carboxy-terminal membrane tethered counterpart named C1 (4) . Interestingly, an additional cleavage occurring at the 90/91 peptide bond in Creutzfeldt-Jakob diseaseaffected brains yielding fragments referred to as N2 and C2 (4) preserves the 106-126 PrP c domain. This peptide has been shown to be neurotoxic in vitro (5) and in vivo (6) . Therefore, understanding the mechanisms underlying PrP c processing could provide a means to interfere with PrP c -dependent effects in both physiological and pathological conditions.
We and others previously established that PrP c metabolism could be either constitutive or regulated by protein kinase C (PKC) (7) and that the disintegrins ADAM10 and ADAM17 were directly responsible for the constitutive and PKC-regulated processing of PrP c respectively (8, 9) . Moreover, we demonstrated that ADAM9 acted as an upstream activator of ADAM10 activity (10) . We very recently showed that stimulation of the M1/M3 muscarinic receptors with several classical or more receptor-specific agonists promotes isoform-specific PKCdependent processing of the cellular prion protein via the catalytic activation ADAM17 upon phosphorylation on its threonine 735 (11, 12) . Moreover, we demonstrated that the conventional PKCα, the novel PKCδ and PKCε, but not the atypical PKCζ isoforms participate in the PDBu-or carbachol-stimulated N1 production (12) . Analysis of the amino acid sequence encompassing the intracytoplasmic Thr735 of ADAM17 indicated that this residue is not part of the canonical K/R-R-K/R/Q-G-T-F/L/V-X consensus sequence that is required for phosphorylation by PKCα, δ or ε isoforms, suggesting that PKC indirectly mediated phosphorylation of ADAM17 and thus, that N1 production required an additional kinase. Cautious analysis of mouse and human ADAM17 sequences revealed that the Thr735 of ADAM17 was located in an A-P-Q-T-P-G sequence corresponding to a canonical ERK1-targeted motif (X-P-X-T-P-X).
We show here that ERK1 is absolutely required for PDBU-and carbachol-induced processing of PrP c and that the inhibition of the ERK1 pathway totally impairs phosphorylation of ADAM17 on its Thr735 and thereby, N1 production. In addition, we establish that, besides its crucial involvement in PrP c regulated processing, ERK1 modulates PrP c protein and mRNA levels by a mechanism implying AP-1-dependent transcriptional control.
Experimental Procedures
Antibodies and pharmacological agents SAF32 is a monoclonal antibody raised against the residues 79-92 of PrP c (13) and was purchased from SPIBio (Montigny le Bretonneux, France). Anti-phospho-threonine polyclonal, anti-ERK1/2 (L34F12) monoclonal and anti-phospho-ERK1/2 (197G2) polyclonal antibodies were from Cell Signaling Technology (Beverly, MA, USA). Anti-β-tubulin and anti-β-actin monoclonal antibodies were purchased from Sigma (St. Quentin-Fallavier, France). Anti-ADAM10 polyclonal antibody was purchased from US Biological (Swampscott, MA, USA). Anti-ADAM9 (C-15) and anti-ADAM17 (H-300) polyclonal antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-HA monoclonal antibody (directed against amino acid residues 98-106 (YPYDVPDYA) of human Influenza virus hemagglutinin) was from Covance (Berkeley, CA, USA). BB3103 (hydroxamic acid-based zinc metalloprotease inhibitor) was kindly provided by British Biotech (Oxford, UK) and GF109203X was from Calbiochem (Fontenaysous-bois, France). The fluorimetric substrate JMV2770 has been developed and characterized previously (14) . Carbachol, phorbol-ester-12-13-dibutyrate (PDBu) and the MEK inhibitor Uo126 were from Sigma. The Akt inhibitor LY294002 and the MEK inhibitor PD98059 were obtained from Cayman (VWR, Fontenay-sous-bois, France).
Cell cultures, cDNA constructs and transfections
Primary cultured neurons, 3F4MoPrP c -and M1 receptor-overexpressing HEK293 cells (respectively referred to as 3F4 and M1R cells throughout the manuscript) were obtained and maintained in culture as previously described (7, 15, 16) . Embryonic mouse fibroblasts (MEFs) (ADAM17 -/-, ERK1 -/-and their respective wildtype controls) (17) were maintained in 50%F12/50%DMEM, 10% FCS. HA-tagged wild-type or dominant negative forms of ERK1 (p44 mapk ), HA-tagged wild-type, constitutively active and dominant negative forms of MEK1 (p45 mapkk ), ADAM17 and 3F4MoPrP c cDNA constructs were previously described (18) (19) (20) (21) (22) . Transient transfections in HEK293 cells and primary cultured neurons were carried out with lipofectamine 2000 reagent (Invitrogen, CergyPontoise, France) while fibroblasts were transiently transfected by means of the mouse embryonic fibroblasts Nucleofector TM kit (Amaxa Biosystems, Koeln, Germany) as described previously (23) .
Western blot analysis
Cells were washed with phosphate-buffered saline (PBS) and resuspended in 300 µl of lysis buffer (10 mM Tris/HCl, pH 7.5, 150 mM NaCl, 0.5% triton X-100, 0.5% deoxycholate, 5mM EDTA) supplemented with a protease inhibitor mixture (Sigma). Protein concentrations were determined by the Bradford method (24) and 25 to 50µg of proteins were separated by SDSpolyacrylamide gel electrophoresis on 8% (ADAM9, ADAM10 and ADAM17) or 12% (PrP c , p53, p44/42, MEK, actin and tubulin) Tris/glycine gels. Proteins were transferred onto nitrocellulose membranes (90 min, 100V), blocked for 2h in 5% non-fat milk and incubated overnight at 4°C with primary antibodies. Bound antibodies were detected using goat anti-mouse or goat anti-rabbit peroxidase-conjugated antibody (Beckman Coulter), and immunological complexes were revealed using ECL methods according to the manufacturer instructions (Roche, Meylan, France). Chemiluminescence was recorded using a Luminescence Image Analyzer LAS-3000 (Raytest, Courbevoie, France) and quantification of captured images was performed using Image J Analyzer software.
Immunoprecipitation and Western blot analysis of N1
Cells cultured in 35-mm dishes were washed with PBS and incubated for 8 hours at 37°C in 1ml serum-depleted DMEM, in the absence (control) or in the presence of various pharmacological agents. Media were collected and supplemented with a protease inhibitor mixture and RIPA (0.1% SDS, 0.5% deoxycholate, 1% NP40, pH 8) then incubated overnight with a 500-fold dilution of the monoclonal antibody SAF32 and protein Asepharose beads (Amersham Biosciences). Beads were washed twice with 500 µl RIPA buffer, then once with 500 µl PBS and submitted to SDS-polyacrylamide gel electrophoresis on a 16.5% Tris/tricine gel. Two-hundred ng of purified recombinant N1 peptide obtained as previously described (11) were run on a separate lane as a standard. Proteins were transferred onto nitrocellulose membranes (45 min at 100V) and incubated overnight at 4°C with the monoclonal antibody SAF32 (dilution 1/2000). Immunological complexes were detected with a goat anti-mouse (dilution 1/2000) peroxidaseconjugated antibody (Beckman Coulter).
Chemiluminescence was recorded using a Luminescence Image Analyzer LAS-3000 (Raytest, Courbevoie, France) and N1 production was quantified using ImageJ analyzer software.
Detection of threonine-phosphorylated ADAM17
M1R-HEK293 cells grown in 35-mm dishes were transiently transfected with ADAM17 cDNA. Twenty-four hours after transfection, cells were pre-treated for 1 hour with various kinase inhibitors and then incubated for 15 min in fresh serum-free media containing 1µM PDBu, or 100µM carbachol. Cells were then collected in 1ml of lysis buffer (10mM Tris/HCl, pH 7.5, 150mM NaCl, 0.5% triton X-100, 0.5% deoxycholate, 5mM EDTA) supplemented with phosphatase inhibitor I and II cocktails and with a protease inhibitor mixture (Sigma). Lysates were centrifuged (5 min, 13000rpm) to remove insoluble material then normalized for protein contents. One mg of proteins was supplemented with RIPA (0.1% SDS, 0.5% deoxycholate, 1% NP40, pH 8) incubated overnight with immunoprecipitating anti-phospho-threonine antibody and protein A-sepharose beads (Amersham Biosciences) (4µg/1mg of proteins).
Immunoprecipitates were washed twice with 500 µl RIPA buffer, then once with 500 µl PBS and subjected to SDS-polyacrylamide gel electrophoresis on an 8% Tris/glycine gel. Proteins were transferred onto nitrocellulose membranes (2h at 100V) and incubated overnight at 4°C with the polyclonal anti-ADAM17 antibody (dilution 1/1000). Immunological complexes were detected with a goat anti-rabbit peroxidase-conjugated antibody (dilution 1/5000) (Beckman Coulter) and revealed as described above.
Measurement
of endogenous ERK1/2 phosphorylation M1R-HEK293 cells grown in 35-mm dishes were pre-treated for 1 hour with various kinase inhibitors and then incubated for 15 min in fresh serum-free media containing 1µM PDBu, or 100µM carbachol. Cells were then collected and treated as above. Lysates were centrifuged (5 min, 13000 rpm) to remove insoluble material then normalized for protein contents. Fifty µg of proteins were separated by SDS-polyacrylamide gel electrophoresis on a 12% Tris/glycine gel. Proteins were transferred onto nitrocellulose membranes (75 min, 100V), blocked for 2h in 5% BSA and incubated overnight at 4°C with anti-phospho-ERK1/2 antibodies (dilution 1/1000 in BSA 5%). Immunological complexes were detected with a goat anti-rabbit peroxidaseconjugated antibody (dilution 1/5000 in 5% BSA) and revealed as described above.
Measurement of disintegrin activity M1R-HEK293, mouse embryonic wild-type and ERK1
-/-fibroblasts were cultured in 6-well plates at 37°C. At 80% of confluence, cells were pretreated (or not) with the PKC inhibitor GF109203X (2µM) or the MEK inhibitor Uo126 (10µM) in the absence or in the presence of the disintegrin inhibitor BB3103 (10µM) for 1 hour and incubated with 1ml of PBS containing the fluorimetric substrate JMV2770 (10µM, (14) ) with or without carbachol (100µM) for various time periods at 37°C. At each kinetic point, 100 µl of medium were taken out and substrate hydrolysis was fluorimetrically recorded (320 and 420 nm as excitation and emission wavelengths, respectively).
Mouse brain tissue preparation
Brains from 7-week-old wild-type and ERK1 -/-mice (17) were homogenized in lysis buffer (10 mM Tris/HCl, pH 7.5 containing 150 mM NaCl, 0.5% Triton X-100, 0.5% deoxycholate, 5mM EDTA). Protein expressions were analyzed by Western blot as described above.
Measurements of PrP
c promoter transactivation The 1543 bp of the 5' promoter region of the human PrP c gene or serial 5'-truncated constructs (1303, 909, 567, 284 and 131 bp constructs) were subcloned into the luciferase reporter vector pGL3basic and used to measure PrP c promoter transactivation as has been extensively described (25) . Cells grown in 12-well plates were cotransfected with full-length or mutant PrP c promoter-luciferase, β-galactosidase (in order to normalize transfection efficiencies) and the indicated cDNAs with lipofectamine (HEK293 cells) or with the Amaxa Nucleofector TM kit (mouse embryonic fibroblasts). After a thirty-sixhours incubation in the presence of carbachol (100µM), luciferase and β-galactosidase activities were measured with appropriate enzyme assay systems (Promega).
Site-directed mutagenesis of PrP c promoter A site-directed mutagenesis kit (QuikChange, Stratagene, La Jolla, CA) was used following the manufacturer's instructions to convert the AP1-binding site nucleotide sequence TGACTCA (26) into TAAATCA. The two following sets of primers were purchased from Eurogentec: pPrPmut AP1-120S, 5'-CAACTCGTTTTTTCCGGTAAATCATTCCC GGCCCTG CTCG-3' (forward primer) and pPrPmut AP1-120AS, 5'-CGAGCAGGGCC GGGAATGATTTACCGGAAAAAACGAGTT G-3' (reverse primer). The altered nucleotides of the AP1 binding site are underlined. The construct was confirmed by sequencing.
Real-time quantitative PCR
Total RNA was extracted and purified from mouse embryonic fibroblasts or HEK293 cells with the NucleoSpin® RNA II kit (MacheryNagel, Hoerdt, France). Two µg of total RNA were reverse-transcribed using oligo (dT) priming and avian myeloblastosis virus reverse transcriptase (Promega, Charbonnières, France). Real-time PCR was performed in an ABI PRISM 5700 sequence detector system (Applied Biosystems) using the SYBR Green detection protocol as outlined by the manufacturer. Specific primers for semi-quantitative or realtime PCR were designed using the Primer Express software (Applied Biosystems, Courtaboeuf, France) and were as follows: Mouse PrP c : forward, 5' -CTG CTG GCC CTC TTT GTG AC-3' and reverse 5' -CTT TTT GCA GAG GCC GAC AT-3'. Human PrP c : forward, 5' -AAT CAA GCA GCA CAC GGT CA-3' and reverse 5' -TCG GTG AAG TTC TCC CCC TT-3'.
Expression levels of human and mouse PrP c genes were normalized by monitoring RNA levels of human GAPDH and mouse γ-actin genes respectively using the following primers: forward, 5' -TGG GCT ACA CTG AGC ACC AG-3' and reverse 5' -CAG CGT CAA AGG TGG AGG AG-3' for human GAPDH; forward 5' -CAC CAT CGG TTG TTA GTT GCC-3' and reverse 5' -CAG GTG TCG ATG CAA ACG TT-3' for mouse γ-actin.
Statistical analysis
Statistical analyses were performed with the PRISM software (GraphPad, San Diego, USA) by using the unpaired t test for pair-wise comparisons.
Results
Inhibitors of the MEK/ERK pathway block the PKC-and M1R-stimulated processing of PrP c and prevent ADAM17 phosphorylation on its threonine 735
In silico examination of human and mouse amino-acid sequences of the ADAM17 cytoplasmic tail revealed that threonine 735, which had been shown to be selectively phosphorylated upon PKC-mediated M1/M3 muscarinic receptor activation (11) , is embedded in an ERK1-specific consensus phosphorylation site ( Figure 1A ). This prompted us to examine the effect of specific inhibitors of its upstream stimulating kinase MEK on regulated PrP c processing. Figure 1B shows that both PKC inhibitor GF109203X (27) and MEK inhibitor Uo126 (a phenylthiobutadiene that specifically inhibits MEK1 and MEK2, see (28) ) impair the carbachol-stimulated increase of BB3103-sensitive JMV2770-hydrolyzing activity, a reporter assay for α-secretase/ADAM activity (14) . Concomitantly, GF109203X and Uo126 abolish PDBu-and carbachol-stimulated N1 secretion in M1R HEK293 cells overexpressing PrP c ( Figure 1C ) while the Akt/PKB specific inhibitor LY294002 remains inactive. None of the inhibitors affects PrP c expression ( Figure 1C ) or constitutive N1 production ( Figure 1D ).
The above pharmacological data clearly linked PKC and muscarinic receptor stimulation to ERK1 and α-secretase activation. We therefore examined whether carbachol and PDBu stimulation could trigger ERK1 and ADAM17 phosphorylation in M1R HEK293 cells. Several lines of data indicate that it is indeed the case. First, a carbachol-induced phosphorylation of ERK1 is observed that is totally impaired by the MEK inhibitors PD098059 (29) and Uo126, the PKC blocker GF109203X but not by the Akt/PKB inhibitor LY294002 ( Figure 2A ) without significantly altering endogenous levels of PrP c -and ERK-like immunoreactivities ( Figure 2A , lower panel). Second, as is observed for ERK phosphorylation, muscarinic receptors and PKC stimulation by carbachol and PDBu trigger ADAM17 phosphorylation that was prevented by PD098059, Uo126 and GF109203X but not LY294002 ( Figure 2B ). The strictly similar responsiveness of ERK and ADAM17 phosphorylation to the above selective pharmacological treatments suggested that muscarinic receptors and PKC stimulation yielding enhanced production of N1 indeed involves a downstream kinase effector, ERK, that ultimately potentiates ADAM17 phosphorylation and activity. Three lines of independent data confirmed this hypothesis. Thus, T735A mutation abolishes both carbachol and PDBu-stimulated N1 production in M1R-HEK293 cells ( Figure 3A ) and prevents carbachol-induced N1 augmentation in cells expressing both ERK1 and M1R ( Figure 3B ). Furthermore, ADAM17, mutation fully blocks CA-MEK-associated increase of N1 production ( Figure 3C ). Altogether, these data clearly indicate that ERK1 indeed requires T735-phosphorylable ADAM17 to stimulate N1 production.
Constitutive activation or reduction of MEK1 and ERK1 modulate carbachol-and PDBuinduced processing of PrP c in human cells and mouse primary neurons
The above clues of a signaling pathway linking muscarinic receptors, PKC, ERK and physiological processing of PrP c based on pharmacological compounds with rather narrow specificity was further reinforced by a series of experiments aimed at more selectively modulating ERK1 and its activating kinase MEK1. Thus, we took advantage of the design of cDNAs encoding HA-tagged wild-type (wt), catalytically inactive dominant negative forms of these two kinases (DN-MEK and DN-ERK) and a constitutively active form of MEK (CA-MEK). Dominant negative forms of ERK1 and MEK were obtained by mutations (T192A and S222A respectively) that abrogate their phosphorylation at regulatory sites (18, 19) while CA-MEK was obtained by replacing two serine residues involved in Raf1/MAPKKK-dependent regulatory phosphorylation of MEK1 by the negatively charged aspartate (S218D/S222D) (20) . Wild-type ERK1 or MEK1 significantly increase carbachol-induced N1 secretion in PrP ctransfected M1R HEK293 cells ( Figure 4A ) while DN-ERK1 or DN-MEK1 expressions totally prevented carbachol-( Figure 4A ) or PDBu-(not shown) stimulated N1 production.
Expression of CA-MEK1 in M1R HEK293 cells transiently transfected with PrP c is per se sufficient to trigger N1 secretion even in nonstimulated conditions ( Figure 4B ). Furthermore, in carbachol-stimulated conditions, the treatment of mock-transfected M1R HEK293 cells with atropine inhibits the secretion of N1, while the secretion of N1 triggered by CA-MEK1 expression remains unaffected by atropine ( Figure 4C ). These results indicate that blockade of endogenous muscarinic receptors do not interfere with constitutively active MEK/ERKassociated N1 increase and therefore demonstrate that the MEK/ERK signal controlling N1 secretion occurs downstream to the muscarinic receptors. Interestingly, as expected, neither wild-type nor dominant negative ERK1/MEK1 are able to modulate N1 production in 3F4 HEK293 cells that are devoid of endogenous muscarinic receptors (30) (Figure 4D ), confirming the importance of M1 receptors as essential mediators of PKC/ERK-dependent processing of PrP c . The above results have been confirmed in primary cultured neurons. First, we establish that N1 production was also potentiated by carbachol and PDBu treatments in neurons ( Figure 5 ). Second, both DN-ERK1 and DN-MEK1 overexpressions restore endogenous levels of N1 produced by untreated cells with no apparent modification of PrP c -like immunoreactivity ( Figure 5) . Altogether, the above data indicate that the pathway described previously also occurs in a physiological neuronal cell system and, therefore, that this cascade was clearly not cell specific but likely ubiquitous.
ERK1 deficiency lowers PrP c expression As could have been anticipated from our previous data, genetic ablation of ERK1 drastically affects PrP c processing. Thus, ERK1
-/-MEFs prepared from ERK1 knockout animals (17) secrete lower amounts of the N1 fragment than wild-type cells ( Figure 6A ). ERK1 gene disruption also fully abolishes the PDBu-and carbachol-stimulated N1 production ( Figure 6C , left panel) in agreement with the phenotype observed in ADAM17 -/-cells (8). Moreover, we are able to partially recover PDBu-and carbachol-stimulated N1 production after transient transfection of wild-type ERK1 cDNA in ERK1-deficient MEFs ( Figure 6C , right panel). However, the very low levels of endogenous N1 secreted by ERK1-deficient cells due to low PrP c expression in these fibroblasts and thus, the difficulty to visualize any modification in N1 production led us to confirm the loss of regulated PrP c processing in ERK1
-/-MEFs after transient transfection of PrP c . As observed with endogenous N1, unlike wild-type fibroblasts, PrP c -transfected ERK1 -/-cells do not respond to carbachol stimulation ( Figure 6D ). Importantly, similar results are obtained when cells are stimulated with PDBu (data not shown). In line with the latter results, carbachol-induced N1 secretion is blocked by the two MEK inhibitors PD098059 and Uo126 in wild-type but not ERK1
-/-cells ( Figure 6E ). Besides the above-described influence of ERK1 on N1 production, an additional feature concerned the consistent decrease of endogenous PrP c -like immunoreactivity triggered by ERK1 deficiency ( Figure 6A and Figure 6C , left panel). This decrease is opposite to the augmentation of PrP c expression observed in ERK1-transfected carbachol-treated M1R/3F4 HEK293 cells ( Figure 4A ) and could suggest an additional putative role for ERK1 in the regulation of PrP c expression. Therefore, one could envision that N1 increase/reduction associated with ERK1 overexpression/ablation could be partly explained by upstream modulation of PrP c expression. In order to specifically address the real impact of ERK1 on PrP c metabolism, we measured α-secretase activity on intact cultured ERK1 -/-and wild-type MEFs by means of the above described fluorimetric assay (14) . Clearly, the BB3103-sensitive hydrolysis of the JMV2770 fluorimetric substrate was strongly affected in intact ERK1 -/-MEFs when compared to wild-type cells ( Figure 6B ) reflecting a direct involvement of this kinase in the regulation of the α-secretase processing of PrP c . However, it was of importance to assess whether and how ERK1 could exert an effect on PrP c expression besides its genuine influence on PrP c processing. We first confirmed that, in vitro, ERK1-deficiency triggered a 50% decrease in PrP c immunoreactivity when compared to wild-type cells ( Figure 7A left panel) . This effect was specific since the levels of the disintegrins ADAM9, ADAM10 and ADAM17 were not affected in ERK1
-/-cells ( Figure 7A right panel) . Finally, we took advantage of ERK1 knockout mice (17) to determine whether ERK1 could control PrP c expression in vivo in mouse brain. Indeed, ERK1-deficient mice show statistically significant reduction of cerebral expression of PrP c compared to wild-type animals ( Figure 7B ).
ERK1 positively controls PrP c expression at a transcriptional level
It is well established that ERK1/2 can modulate the transcription of several genes (see (31) Figure 9D ). This set of data clearly shows that ERK controls PrP c promoter transactivation independently of its effect on ADAM17 and therefore, that ERK1-associated modulation of ADAM17-increased N1 production could not be accounted for by the sole increase in the expression of its PrP c precursor. We then examined by which mechanisms ERK1 could control PrP c promoter transactivation, mRNA and protein levels. The role of ERK1 in the regulation of gene transcription has been well documented. ERK1/2 mainly operates through two main mechanisms, i.e the phosphorylation of Sp1 that binds to GC box elements or via the phosphorylation of cfos that associates with phosphorylated cjun to form an AP-1 active transcription factor that interacts with one specific AP-1-recognizing sequence (see (31) 
Discussion
Although the importance of the cellular prion protein in the development of transmissible spongiform encephalopathies (TSEs) has been extensively documented (see (1) for review), less is known concerning the physiological roles fulfilled by this protein. Because PrP c -knock out mice are viable and fertile with no apparent dysfunction (32) , it has long been thought that PrP c does not participate in any vital physiological process. However, subsequent studies showed that PrP c could contribute to various biological functions such as lymphocyte activation, cell adhesion, synaptic transmission and apoptosis (see (3) for review). Noteworthy, PrP c is subjected to a physiological proteolytic breakdown at its 111/112 peptide bond (4). There exist strong evidence that the disintegrins ADAM10 and ADAM17 are responsible for the constitutive and PKC-regulated pathway (8, 14) , respectively. It should be noted however that a few studies failed to find evidence for an involvement of ADAM proteases on PrP c processing but this discrepancy may be likely explained by distinct experimental conditions in which recombinant soluble enzyme were used or because only constitutive processing was examined (33, 34) .
This proteolytic event further complicates our understanding of PrP c -related biological effects and raises the question whether this proteolytic attack represents a degradation process aimed at clearing full-length PrP c or indeed illustrates a maturation step yielding biologically active metabolites. Concerning the C1 fragment, we previously showed that its overexpression potentiates staurosporine-induced apoptosis in vitro (23) as PrP c does (35) (36) (37) . As far as the N1 fragment is concerned, the first indirect demonstration of an N1-related function was brought by in vivo studies showing that transgenic mice expressing N-terminally truncated PrP c constructs displayed exacerbated neuro degeneration and that this phenotype strictly requires a full depletion of the C-terminal N1 sequence, thereby suggesting a putative N1-associated neuroprotective effect. (38) (39) (40) . We brought the definitive and direct proof that N1 indeed conveys neuroprotection by showing that treatment with the recombinant N1 peptide or stimulation of N1 production by muscarinic agonists invariably protect cells from hypoxiainduced p53-dependent apoptosis and ischemia in vitro and in vivo (41) . Noteworthy, it has been very recently established that ablation of neuronal PrP c triggers a chronic demyelinating polyneuropathy (CDP) due to impaired peripheral myelin maintenance (42) . This was the first demonstration of a PrP c -associated pathology of the central nervous system unrelated to TSEs. Interestingly, CDP can be rescued by PrP c variants that undergo disintegrinmediated proteolytic processing at the 111/112 site but not by cleavage-resistant variants. Therefore, the N1 and/or C1 fragments derived from the physiological processing of PrP c are essential for myelin maintenance (42) . Altogether, and since we established that the N1-associated neuroprotective function was dominant over the C1-mediated toxic effect (41) , these data suggests that up-regulating α-secretase processing of PrP c could convey beneficial effects in normal conditions as well as in pathological conditions unrelated to prion diseases. Therefore, a possible track would be to activate the PKC-regulated α-secretase hydrolysis of PrP c at the 111/112 peptide bond. Phosphorylation of ADAM17 on its intracytoplasmic threonine residue at position 735 is necessary to activate this pathway (11) . This amino acid is embedded in a consensus phosphorylation site targeted by ERK1/2. We therefore examined whether this kinase was directly responsible for ADAM17 activation through Thr735 phosphorylation and, thereby, could act as a direct and functional activator of PKC-regulated α-secretase processing of PrP c . Four lines of data indicate that it is indeed the case. First, inhibition of MEK, a kinase occurring upstream in the MEK/ERK signalling cascade reduces α-secretase JMV2770-hydrolyzing activity and drastically impairs N1 secretion and ADAM17 phosphorylation. Second, transient overexpression of wild-type or constitutively active forms of these two kinases in both human cells and murine primary neurons activate PDBuand carbachol-dependent N1 production while dominant negative kinases reduce the recovery of N1 in the conditioned medium. Third, ERK1 deletion impairs PKC-regulated α-secretase activity and abolishes PDBu-and carbacholdependent N1 secretion. Fourth, ERK1 cDNA transfection in ERK1 -/-cells rescues carbacholdependent secretion of N1. Overall, we propose that M1/M3 muscarinic receptors activation triggers ADAM17-dependent processing of PrP c at the 111/112 site after initiating the MEK/ERK pathway depicted in green in Figure 11 . ERK1-mediated control of PrP c processing is not the only example of such an ERK1-controlled proteolytic conversion. Thus, the neurotrophin receptor TrkA shedding is also stimulated through an ERK1-dependent phosphorylation of ADAM17 at its Thr735 in both in vitro assay and cultured cells (43) . Moreover, this molecular event induces maturation and trafficking of ADAM17 to the plasma membrane thereby explaining the gain of activity of the ERK1-dependent threonine735-phosphorylated ADAM17 form (44) . However, this cascade is not ubiquitous since we recently demonstrated that α-secretase-regulated processing of βAPP indeed involved ADAM17 and PKCs but in an ERK-1 independent manner (45 (49) . We clearly showed that the transcription factor AP-1, but not Sp1, contributes, at least partly, to the ERK1-dependent control of PrP c . Thus, cDNA constructs harbouring various 5' deletions indicate that the ablation of the promoter region containing the AP-1 binding site, but not Sp1-related GC box elements, strongly impaired PrP c promoter transactivation. Accordingly, inactivating mutations of the AP-1 binding sequence in the full-length promoter significantly reduce its promoter transactivation in two different cell lines. However, the fact that the extent of inhibition triggered by the -284/-131 deletion was higher than that resulting from the AP-1 site mutation (55-70% compared to 30% inhibition, Figure 10C ), suggests that additional transcription factors, the binding sites of which would be located within position -284/-131, may also modulate PrP c expression. It is noteworthy that binding sites for Ets-1, NF-AT, AP-2, YY1 and E4BP4 have been delineated in such a region (25, 50) . Altogether, these data clearly established an important functional contribution of ERK1 and AP-1 in the positive control of PrP c transcription ( Figure 11 , orange arrowheads).
Since ERK increases both PrP c expression and the production of its α-secretase-derived catabolite N1, one can question whether the increase of N1 is just the consequence of an upstream elevation of its precursor PrP c or if ERK triggers dual and fully independent phenotypes. Close examination of some of the data indicates that the latter hypothesis is more likely. Thus, PDBu-and carbachol-stimulated N1 production is abolished in ERK-deficient cells while PrP c expression remains similar in treated and untreated null fibroblasts. This shows that agonist-dependent phosphorylation of ADAM17 and subsequent N1 production is impaired by ERK1 ablation while reduction of PrP c still stands. Second, ERK-1 rescues the carbachol-induced increase in N1 production without affecting PrP c expression levels. This set of data reflects a clear discrimination between the two events that could be likely accounted for by distinct time frames for the two processes, with an early phase involving ADAM17 phosphorylation and enhanced PrP c catabolism and a later phase needing a necessary delay to activate the transcriptional machinery.
Another interesting aspect of this work concerns the putative functional cross-talk between PrP c and the MEK/ERK signaling pathway.
Thus, PrP c cross-linking or overexpression triggers ERK phosphorylation in neuronal and non-neuronal cells (51) (52) (53) (54) (55) . Other studies established that the specific PrP c ligand stress-inducible protein 1 (STI1) (56) likely accounts for PrP c -dependent ERK phosphorylation in neurons and astrocytes (57) (58) (59) . Therefore, the MEK/ERK cascade could self stimulate its own signalling via the increase of PrP c expression and thereby explain both ERK and PrP c -related protective phenotypes documented in certain cell systems (3, 60, 61) . Along with this hypothesis, one could envision that part of an ERK1-dependent PrP c -associated antiapoptotic function could be mediated by an ERK-1-mediated increase in N1 since we recently characterized this catabolite as a neuroprotective factor both in vitro and in vivo (41) .
In other cases, PrP c has been shown to be toxic and trigger p53-dependent cell death (35) (36) (37) . In this case, the ERK-1 mediated production of N1 could be seen as a cellular response to counterbalance PrP c -mediated toxicity. This hypothesis seems to be supported by the observation that in cells overexpressing a PrP c construct lacking the 32-134 amino terminal sequence (that encompasses most of the N1 domain), ERK phosphorylation is still stimulated but leads to cell death, oxidative injury and neurodegeneration (62) (63) (64) . This could be due to the fact that while N-terminally truncated PrP c is increased, its neuroprotective counterpart N1 is lacking. Overall, our study suggests that under normal conditions, ERK1 contributes to cell survival and neuroprotection through the augmentation of N1 secretion (41) via an increase in ADAM17 activity and PrP c expression. It is likely that in pathological situations, N1 could temporarily compensate for the PrP scrapie-associated toxicity and cell death and thereby partly could explain the long asymptomatic time course of TSEs. (B) Cultured M1R-HEK293 cells were pretreated or not for 1 hour with GF109203X (2µM) or Uo126 (10µM) and monitored for their BB3103-sensitive JMV2770-hydrolyzing activities in the absence or in the presence of carbachol (car, 100µM) as described in Experimental Procedures. Aliquots of 100µl were collected at the indicated times and the fluorescence was recorded as described in Experimental Procedures. A typical time course of BB3103-sensitive JMV2770 hydrolysis under various conditions is illustrated on the left panel and quantification is shown on the right panel (white circles, nonstimulated (ns); black circles, carbachol-(carba) stimulated; grey squares, carbachol+GFX109203X (GFX); grey circles, carbachol+U0126). Statistical analyses performed at 60 min (right panel) are the means ± SEM of 3 independent experiments. *p<0.05; **p<0.001.
(C) M1R-HEK293 cells grown in 35mm-dishes were transiently transfected with Mo3F4PrP c cDNA as described in Experimental Procedures. Twenty-four hours after transfection, cells were pretreated (+) or not (-) for 1 hour with the indicated inhibitors. Media were removed and cells were incubated for 8 hours in the absence (-) or in the presence (+) of PDBu (left panel) or carbachol (right panel). N1 content in conditioned media as well as PrP c and tubulin immunoreactivities in cell lysates were analysed as described in Experimental Procedures. Bars corresponding to the densitometric analyses are expressed as a percentage of control (non-stimulated cells) taken as 100 and represent the means ± SEM of 6 independent experiments. *p<0.05; **p<0.005; ***p<0.0001; NS, non-statistically significant. (D) HEK-M1 cells were treated with the indicated inhibitors for 30 min. After removal of media, cells were incubated for 8 hours without (-) or with (+) PDBu (1µM, upper panel) or carbachol (100 µM, lower panel) then constitutive or regulated N1 were monitored as described in Experimental Procedures. Bars corresponding to the densitometric analyses of N1 are expressed as a percentage of control (non-stimulated cells in absence of inhibitors) taken as 100 and represent the means ± SEM of 3 independent experiments. *p<0.0005; NS, non-statistically significant. Figure 2 . Inhibitors of the ERK/MEK pathway prevent PDBu-and carbachol-dependent ADAM17 phosphorylation on its threonine residue (A) M1R-HEK293 cells grown in 35mm-dishes were pretreated for 1 hour without (-) or with (+) the indicated inhibitors (PD098059, 20µM; LY294002, 5µM; Uo126, 10µM; GF109203X, 2µM) and then incubated for 15 min with (+) or without (-) the indicated concentrations of carbachol (upper panels) or with PDBu (1µM) (lower panel). Cells were collected, lysed as described in Experimental Procedures, analyzed by 12% glycine SDS-PAGE and western blotting using antibodies specifically directed against phospho-ERK1/2 (P-ERK1/2), total ERK1/2 (ERK1/2), PrP c or actin. (B) M1R-HEK293 cells grown in 35mm-dishes were transiently transfected with empty pcDNA3 or ADAM17 cDNA. Twenty-four hours after transfection, cells were pre-treated for 1 hour with inhibitors as in A and then stimulated (+) or not (-) with PDBu (1µM) or carbachol (100µM) for 15 min as indicated. Threonine-phosphorylated ADAM17 (P-Thr-ADAM17) was monitored by immunoprecipitation of 500µg of proteins with a specific antibody directed against phospho-threonine and western blotting with an ADAM17 specific antibody as described in Experimental Procedures. Fifty µg of the same samples were then submitted to 8% (ADAM17) or 12% (PrP c and actin) glycine SDS-PAGE and western blotted with specific corresponding antibodies as described in Experimental Procedures. All illustrations are typical data of three independent experiments. . Dominant negative ERK1 and MEK1 abrogate PDBu-and carbachol-stimulated endogenous production of N1 in mouse primary cultured neurons Primary neurons were prepared from 14-day-old mouse embryos and cultured for 4 days then cells were transfected with empty pcDNA3 (DNA3) or with DN-ERK1 or DN-MEK1 cDNAs as indicated. Twenty-four hours after transfection, cells were incubated for 8 hours with 1ml of DMEM in the absence (CT) or in the presence of PDBU (1µM) (right panel) or carbachol (100 µM) (left panel). The media were taken out and N1 was immunoprecipitated and western blotted as described in Experimental Procedures. PrP c , tubulin and HA-tagged ERK1 and MEK1 contents were detected in cell lysates by separating 50µg of proteins by 12% glycine SDS-PAGE as described in Experimental Procedures. Bars correspond to densitometric analyses of N1 and are expressed as a percentage of control (non-stimulated cells transfected with pcDNA3) taken as 100 and represent the means ± SEM of 6 independent experiments. * p<0.0001; NS, non-statistically significant. Note that the upper left N1 blot was spliced for a clearer data presentation but that all the lanes derive from the same blot. c promoter transactivation (C) and mRNA levels (D) were analyzed as described in Experimental Procedures. Bars correspond to the ratios of luciferase/β-galactosidase activities normalized by protein concentrations (C) or mRNA levels measured by realtime PCR (D), and are expressed as a percentage of control (pcDNA3-transfected cells) taken as 100 and are the means ± SEM of 9 independent determinations. * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. Stimulation of M1/M3 muscarinic receptors triggers PKC-dependent activation of the MEK/ERK signaling pathway. Activated ERK1 then 1) directly phosphorylates ADAM17 on its intracytoplasmic threonine residue at position 735, thereby increasing ADAM17 activity, the processing of PrP c at the 111/112 peptidyl bond and the secretion of the neuroprotective N1 fragment; 2) increases PrP c promoter transactivation and mRNA levels in an AP1-dependent manner. Mutational analysis indicates that AP-1 directly activates PrP c transcription likely after formation of well documented ERK-1-dependent build-up with phosphorylation of c-Fos and its subsequent association with phospho-c-Jun (65) . Therefore, under physiological conditions, ERK1 participates via two distinct processes (elevation of both substrate levels and enzyme activity) to an overall increased of the N1-associated neuroprotective phenotype.
